Get the Stockscreener App
3.76
2.34%
-0.09
After Hours:
3.76
Inventiva Adr stock is traded at $3.76, with a volume of 350.66K.
It is down -2.34% in the last 24 hours and down -30.88% over the past month.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
See More
Previous Close:
$3.85
Open:
$3.85
24h Volume:
350.66K
Relative Volume:
0.80
Market Cap:
$785.64M
Revenue:
$4.90M
Net Income/Loss:
$-399.99M
P/E Ratio:
-1.3236
EPS:
-2.8407
Net Cash Flow:
$-122.90M
1W Performance:
-3.84%
1M Performance:
-30.88%
6M Performance:
-16.07%
1Y Performance:
+8.21%
1-Day Range:
$3.72
$3.85
1-Week Range:
$3.69
$4.02
52-Week Range:
$2.8536
$7.9825
Inventiva Adr Stock (IVA) Company Profile
Compare IVA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVA
Inventiva Adr
|
3.76 | 804.45M | 4.90M | -399.99M | -122.90M | -2.8407 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inventiva Adr Stock (IVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-19-26 | Initiated | Truist | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-12-26 | Initiated | Leerink Partners | Outperform |
| Jan-07-26 | Resumed | UBS | Buy |
| Nov-06-25 | Initiated | Wolfe Research | Outperform |
| Sep-03-25 | Resumed | H.C. Wainwright | Buy |
| Aug-27-25 | Initiated | Piper Sandler | Overweight |
| Feb-21-25 | Initiated | TD Cowen | Buy |
| Nov-12-24 | Initiated | UBS | Neutral |
| Oct-27-23 | Initiated | Canaccord Genuity | Buy |
| May-31-23 | Initiated | ROTH MKM | Buy |
| May-19-23 | Upgrade | Societe Generale | Sell → Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Nov-15-22 | Downgrade | Societe Generale | Buy → Sell |
| Mar-08-21 | Downgrade | Societe Generale | Buy → Sell |
| Aug-05-20 | Initiated | ROTH Capital | Buy |
| Aug-04-20 | Initiated | Guggenheim | Buy |
| Aug-04-20 | Initiated | Stifel | Buy |
View All
Inventiva Adr Stock (IVA) Latest News
Down 31.8% in 4 weeks, here's why Inventiva (IVA) looks ripe for a turnaround - MSN
Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing - GlobeNewswire Inc.
Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround - Yahoo Finance
IVA SEC FilingsInventiva S.A. 10-K, 10-Q, 8-K Forms - Stock Titan
Here's Why Inventiva (IVA) Is a Great 'Buy the Bottom' Stock Now - MSN
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Phreesia, Service Properties Trust, Inventiva and other big stocks moving lower in Tuesday's pre-market session - MSN
Inventiva (NASDAQ:IVA) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Phreesia, Service Properties Trust, Inventiva And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Update - MarketBeat
Zenas Biopharma, Daqo New Energy and other big stocks moving lower in Friday's pre-market session - MSN
Zenas Biopharma, Daqo New Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Does Inventiva (IVA) have the potential to rally 136.34% as Wall Street analysts expect? - MSN
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sahm
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives $17.00 Consensus PT from Brokerages - Defense World
Short Interest in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Drops By 20.4% - MarketBeat
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Average Rating of "Buy" from Analysts - MarketBeat
Does Inventiva (IVA) Have the Potential to Rally 136.34% as Wall Street Analysts Expect? - Finviz
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Inventiva CEO: Phase 3 Lanifibranor MASH Trial Fully Enrolled, Top-Line Data Due in H2 - Yahoo Finance
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Sees Significant Increase in Short Interest - MarketBeat
Are You Looking for a Top Momentum Pick? Why Inventiva S.A. Sponsored ADR (IVA) is a Great Choice - Yahoo Finance
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Inventiva SA ADR Trade Ideas — LSX:A2P796 - TradingView
Inventiva (NASDAQ:IVA) Shares Gap Up on Analyst Upgrade - Defense World
Inventiva’s (IVA) “Buy” Rating Reiterated at UBS Group - Defense World
Wall Street Analysts Predict a 200.59% Upside in Inventiva (IVA): Here's What You Should Know - primepublishers.com
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Inventiva (NASDAQ:IVA) Sees Strong Trading VolumeHere's Why - MarketBeat
Debt to assets ratio of Inventiva SA ADR – LSX:A2P796 - TradingView — Track All Markets
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket - Benzinga
Novo Nordisk, Waldencast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Inventiva (NASDAQ:IVA) Upgraded at Wolfe Research - Defense World
Inventiva Stock Falls 9% Following Announcement of a Dilutive Financing Program - Idéal Investisseur
Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Inventiva SA Reports Progress and Challenges in 2025 - The Globe and Mail
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Inventiva Adr Stock (IVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):